Biosimilars

Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses biosimilars and the potential impact on patient care.

Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.

With drugs that achieve similar clinical outcomes, it will ultimately come down to financial differentiation that can determine which drugs lead the market.

Biosimilars are a potential solution to the ever-growing problem of high specialty drug costs.

Top news of the week from Specialty Pharmacy Times.

New policies that aim to help generic drug makers move their products through the development and approval processes more efficiently have been announced by FDA Commissioner Scott Gottlieb, MD.

A new 5-part video series released by the FDA is part of a larger education and outreach effort about biosimilars and interchangeable products.

Top news of the week from Specialty Pharmacy Times.

Retacrit gains FDA approval as a biosimilar to Epogen/Procrit for the treatment of anemia caused by chronic kidney disease, chemotherapy, or in patients with HIV.

Significant savings on biologic drugs from biosimilars may not be realized until litigation regarding patents is settled.

Ron Lanton III, Esq, President, True North Political Solutions, discusses how drug manufacturers have responded to the emergence of biosimilars thus far.

Imraldi, a biosimilar referencing Humira, is expected to launch initially in Europe.

Innovative specialty drugs could result in more payers adopting value-based contracting.

CAR T-cell therapies and biosimilars require new strategies compared with traditional drugs.

Top news of the week from Specialty Pharmacy Times.

Understanding biosimilars will be crucial for pharmacists as interchangeability comes into play.

Biosimilars for rituximab, trastuzumab, and bevacizumab are currently approved for use in the European Union.

Current developments and innovations that will shape the future of specialty pharmacy.

Ron Lanton III, Esq., President, True North Political Solutions, speaks about proposed legislation that could bolster the emergence of biosimilars.

In an effort to evaluate whether switching from a reference biologic to a biosimilar could lead to altered clinical outcome, a research team, led by Hillel Cohen, PhD, conducted a systematic literature review of all available switching studies.

The United States has been slow to embrace biosimilars, which may impact the overall effect they have on prescription drug spending.

The new purchasing efforts may help increase biosimilar uptake and lower drug costs.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.